Taconic and Oligomerix to Collaborate on Tau Mouse Model Characterization for Use in Alzheimer’s Disease Research

Identification of a Tau Oligomer Structure That is Toxic to Neurons

Oligomerix Awarded Phase IIB Grant From the NIH to Discover Drugs that Inhibit Alzheimer’s Disease Progression

Oligomerix, Inc. to Present Multiple Posters Highlighting its Tau-Focused Technology During the Annual Alzheimer’s Association International Conference

Oligomerix, Inc. Completes Series B Financing

Oligomerix, Inc. Completes $2 Million Series A Financing

SFN 2010 Press Release: Validation of Extracellular Tau Oligomer Target

Oligomerix Awarded Phase II NIH Grant to Discover Novel Drugs for Alzheimer’s Disease

Oligomerix Announces Board Changes: Vic Micati Appointed Chairman and Jack Pasini Appointed Company Director and Chief Commercial Officer

Oligomerix Awarded NIH Grant to Develop Novel Biomarkers for Alzheimer’s Disease